July 23, 2020
The Patent Trial and Appeal Board ruled Thursday that Moderna Therapeutics Inc. failed to invalidate claims in Arbutus Biopharma Corp.'s patent covering a drug-delivery composition as obvious or anticipated based on overlapping composition ranges, finding that prior art does not explicitly disclose such ranges.
April 22, 2020
The Patent Trial and Appeal Board wrestled Wednesday with Arbutus Biopharma's argument that its rival failed to prove that claims in its patent covering a drug delivery composition are obvious on their face because their formulations overlap with those disclosed in existing technology.
July 25, 2019
The Patent Trial and Appeal Board has agreed to review a drug delivery formulation patent owned by Arbutus Biopharma Corp., a company set on curing hepatitis B.